First proof of pharmacology in humans of a novel glucagon receptor antisense drug

Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2015, Pages 298-306

  Van Dongen, Marloes G J ^a   Geerts, Bart F ^b   Morgan, Erin S ^c   Brandt, Teresa A ^c   De Kam, Marieke L ^a   Romijn, Johannes A ^b   Cohen, Adam F ^a   Bhanot, Sanjay ^c   Burggraaf, Jacobus ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense oligonucleotides (ASO); diabetes mellitus type 2; glucagon; glucagon receptor (GCGR); glucose

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; CREATININE; GLUCAGON; GLUCAGON RECEPTOR ANTAGONIST; GLUCOSE; INTERLEUKIN 6; ISIS 325568; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL; OLIGONUCLEOTIDE PHOSPHOROTHIOATE;

ADULT; AGED; ANIMAL EXPERIMENT; ANTISENSE THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISTRIBUTION HALF-LIFE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEVER; FOLLOW UP; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLUCAGONEMIA; INJECTION SITE REACTION; KIDNEY FUNCTION; LIMIT OF QUANTITATION; MALAISE; MALE; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIPLE DRUG DOSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URINARY EXCRETION; ADOLESCENT; BLOOD; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; MIDDLE AGED; NETHERLANDS; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; GLUCAGON; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; LIVER; MALE; MIDDLE AGED; NETHERLANDS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; RECEPTORS, GLUCAGON; YOUNG ADULT;

EID: 84929954732     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.396     Document Type: Article

References (19)

1. Unger RH, Orci L,. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975; 1: 14-16.
2. Baron AD, Schaeffer L, Shragg P, Kolterman OG,. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987; 36: 274-283.
3. Hansen LH, Abrahamsen N, Nishimura E,. Glucagon receptor mRNA distribution in rat tissues. Peptides. 1995; 16: 1163-1166.
4. Svoboda M, Tastenoy M, Vertongen P, Robberecht P,. Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol Cell Endocrinol. 1994; 105: 131-137.
5. Brand CL, Rolin B, Jorgensen PN, et al., Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia. 1994; 37: 985-993.
6. Brand CL, Hansen B, Gronemann S, Boysen M, Holst JJ,. Sub-chronic glucagon neutralisation improves diabetes in ob/ob mice. Diabetes. 2000; 49: A81.
7. Petersen KF, Sullivan JT,. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001; 44: 2018-2024.
8. McCormack JG, Westergaard N, Kristiansen M, Brand CL, Lau J,. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr Pharm Des. 2001; 7: 1451-1474.
9. Baker BF, Monia BP,. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta. 1999; 1489: 3-18.
10. Crooke ST, Bennett CF,. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 1996; 36: 107-129.
11. Liang Y, Osborne MC, Monia BP, et al., Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 2004; 53: 410-417.
12. Sloop KW, Cao JX, Siesky AM, et al., Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest. 2004; 113: 1571-1581.
13. Kwoh TJ,. An overview of clinical safety experience of first- and second-generation antisense oligonucleotides. In:, Crooke ST, ed. Antisense Drug Technology: Principles, Strategies, and Applications. Boca Raton: Taylor & Francis. 2007: 365-399.
14. van Dongen MG, Geerts BF, Bhanot S, et al., Characterization of a standardized glucagon challenge test as a pharmacodynamic tool in pharmacological research. Horm Metab Res. 2014; 46: 269-273.
15. Yu RZ, Geary RS, Levin AA,. Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides. Curr Opin Drug Discov Dev. 2004; 7: 195-203.
16. Leeds JM, Graham MJ, Truong L, Cummins LL,. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem. 1996; 235: 36-43.
17. Reinauer H, Gries FA, Hubinger A, et al., Determination of glucose turnover and glucose oxidation rates in man with stable isotope tracers. J Clin Chem Clin Biochem. 1990; 28: 505-511.
18. Rosenblatt J, Wolfe RR,. Calculation of substrate flux using stable isotopes. Am J Physiol. 1988; 254: E526-E531.
19. Henry SP, Kim TW, Kramer-Stickland K, Zanardi TA, Fey RA, Levin AA,. Toxicologic properties of 2′-O-methoxyethyl chimeric antisense inhibitors in animals and man. In:, Crooke ST, ed. Antisense Drug Technology: Principles, Strategies, and Applications. Boca Raton: Taylor & Francis; 2007: 327-363.